The Role of Serotonin in Intensive Care Patients (SERO-22)
2022年5月27日 更新者:Morten Rostrup、Oslo University Hospital
The Role of Serotonin in Respiratory and Circulatory Failure in Intensive Care Patients
Sepsis, cardiac arrest and multiple trauma are potentially life-threatening conditions and common reasons for intensive care unit (ICU) admission.
The aim of this study is to investigate the role of the signaling substance serotonin in blood in these conditions.
研究概览
研究类型
观察性的
注册 (预期的)
250
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Morten Rostrup, MD PhD
- 电话号码:+4722119338
- 邮箱:morteros@uio.no
研究联系人备份
- 姓名:Nikolai R Aarskog, MD
- 电话号码:+4722119338
- 邮箱:n.r.aarskog@medisin.uio.no
学习地点
-
-
-
Oslo、挪威、0450
- 招聘中
- Oslo University Hospital Ullevål
-
接触:
- Morten Rostrup, MD PhD
- 电话号码:+4722119338
- 邮箱:morteros@uio.no
-
接触:
- Nikolai R Aarskog, MD
- 电话号码:+4722119338
- 邮箱:n.r.aarskog@medisin.uio.no
-
副研究员:
- Aleksander R Holten, MD PhD
-
副研究员:
- Knut Erik Hovda, MD PhD
-
副研究员:
- Geir Øystein Andersen, MD PhD
-
副研究员:
- Vibeke N Kjær
-
副研究员:
- Eirik Qvigstad, MD PhD
-
副研究员:
- Kjetil Sunde, MD PhD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
全部
取样方法
非概率样本
研究人群
Patients with sepsis or septic shock, cardiac arrest with ROSC or severe multiple trauma, admitted to ICU and receiving mechanical ventilation will be screened for inclusion.
A group of healthy controls will also be included.
描述
ICU-PATIENTS
Inclusion criteria:
- Active treatment of sepsis, septic shock, cardiac arrest with ROSC or severe multiple trauma.
- Age over 18 years
- Written consent from the patient or preliminary consent from the next of kin.
- Receiving mechanical ventilator treatment upon inclusion.
- Arterial and central venous cannulas present.
Exclusion criteria:
- Withdrawal of consent
- Serotonergic carcinoid syndrome, short bowel or other considerable comorbidity altering serotonin content in blood.
- Intoxication prior to ICU admission.
HEALTHY CONTROLS
Inclusion criteria:
- Age over 18 years and signed written consent.
- Conformed to diet and activity restrictions.
Exclusion criteria:
- Any acute illness or injury
- Ongoing autoimmune, malignant, infectious, or other inflammatory disease.
- Severe psychiatric disease or drug abuse.
- Use of any medication except oral contraceptives last two weeks.
- Withdrawal of consent.
ICU CONTROLS
Inclusion criteria:
- Status epilepticus, encephalitis, stroke, or other localized neurological disease.
- Age over 18 years
- Written consent from the patient or preliminary consent from the next of kin.
- Receiving mechanical ventilator treatment upon inclusion.
- Arterial and central venous cannulas present.
Exclusion criteria:
- Withdrawal of consent
- Clinical signs of infection with focal symptoms or temperature over 38,0°C.
- Biochemical signs of infection or inflammation with leukocytes > 11 x 10^9/l, CRP > 15 mg/l, or PCT > 0,10 μg/l.
- Respiratory failure with PaO2/FiO2 ratio < 40 kPa.
- Circulatory failure with MAP < 60 or need for pressor treatment prior to sedation.
- Thrombocytopenia or thrombocytosis with platelets < 100 or > 400 x 10^9/l.
- Serotonergic carcinoid syndrome, short bowel or other considerable comorbidity altering serotonin content in blood.
- Extracranial autoimmune or malignant disease.
- Severe psychiatric disease or drug abuse.
- Intoxication or physical trauma prior to ICU admission.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Healthy controls
Healthy volunteers without conditions altering serotonin content in blood.
|
|
Sepsis group
Patients with sepsis or septic shock admitted to ICU and receiving mechanical ventilation.
|
|
Cardiac arrest group
Patients with cardiac arrest and ROSC admitted to ICU and receiving mechanical ventilation.
|
|
Multiple trauma group
Patients with severe multiple trauma admitted to ICU and receiving mechanical ventilation.
|
|
ICU control group
Patients with isolated neurological disease admitted to ICU and receiving mechanical ventilation.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PPP-serotonin
大体时间:As soon as possible after ICU admission. No more than 3 days after admission.
|
Serotonin in platelet poor plasma
|
As soon as possible after ICU admission. No more than 3 days after admission.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PPP-serotonin
大体时间:End of first week at ICU, an average of 5 days after admission.
|
Serotonin in platelet poor plasma
|
End of first week at ICU, an average of 5 days after admission.
|
|
Platelet serotonin
大体时间:As soon as possible after ICU admission. No more than 3 days after admission.
|
Serotonin in platelets
|
As soon as possible after ICU admission. No more than 3 days after admission.
|
|
Platelet serotonin
大体时间:End of first week at ICU, an average of 5 days after admission.
|
Serotonin in platelets
|
End of first week at ICU, an average of 5 days after admission.
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma 5-HIAA
大体时间:As soon as possible after ICU admission. No more than 3 days after admission.
|
5-hydroxyindoleacetic acid in plasma
|
As soon as possible after ICU admission. No more than 3 days after admission.
|
|
Plasma 5-HIAA
大体时间:End of first week at ICU, an average of 5 days after admission.
|
5-hydroxyindoleacetic acid in plasma
|
End of first week at ICU, an average of 5 days after admission.
|
|
Urine 5-HIAA
大体时间:As soon as possible after ICU admission. No more than 3 days after admission.
|
5-hydroxyindoleacetic acid in urine
|
As soon as possible after ICU admission. No more than 3 days after admission.
|
|
Urine 5-HIAA
大体时间:End of first week at ICU, an average of 5 days after admission.
|
5-hydroxyindoleacetic acid in urine
|
End of first week at ICU, an average of 5 days after admission.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Morten Rostrup, MD PhD、Oslo University Hospital, University of Oslo
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2022年5月25日
初级完成 (预期的)
2024年12月31日
研究完成 (预期的)
2024年12月31日
研究注册日期
首次提交
2022年5月6日
首先提交符合 QC 标准的
2022年5月18日
首次发布 (实际的)
2022年5月23日
研究记录更新
最后更新发布 (实际的)
2022年5月31日
上次提交的符合 QC 标准的更新
2022年5月27日
最后验证
2022年5月1日
更多信息
与本研究相关的术语
其他研究编号
- REK366749
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.